<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413400</url>
  </required_header>
  <id_info>
    <org_study_id>2006-P-001060</org_study_id>
    <nct_id>NCT00413400</nct_id>
  </id_info>
  <brief_title>Study of TNF-Antagonism in the Metabolic Syndrome (II)</brief_title>
  <official_title>Effects of Etanercept in Patients With the Metabolic Syndrome (II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate whether etanercept will result in improved inflammatory indices,
      glucose tolerance and endothelial function in patients with the metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic syndrome is an increasingly prevalent disorder associated with elevated risks of
      type II DM (diabetes mellitus) and cardiovascular morbidity and mortality. A subclinical
      inflammatory state is thought to contribute to the pathophysiology of metabolic syndrome,
      insulin resistance, and coronary artery disease (CAD). Tumor Necrosis Factor (TNF) -alpha is
      an inflammatory cytokine that is increased in a spectrum of inflammatory diseases as well as
      in insulin resistance. TNF-alpha antagonists are clinically effective in the inflammation of
      arthritides, and have recently been shown by our group to decrease inflammatory
      cardiovascular risk markers in metabolic syndrome. Data suggests that adiponectin, a recently
      discovered adipocytokine that may protect against the development of insulin resistance and
      atherosclerosis, may be downregulated by TNF-alpha. In addition, population based studies
      have shown that those with the highest levels of TNF-alpha have an increased relative risk of
      cardiovascular morbidity while rheumatoid arthritis patients treated with TNF-alpha blockade
      appear protected from cardiovascular disease. We will perform a 6-month study in which we
      will administer etanercept, a TNF-alpha receptor fusion protein, to subjects with metabolic
      syndrome to investigate its effect on surrogate markers of cardiovascular disease, including
      inflammatory markers, adiponectin and glucose tolerance and endothelial function. The results
      of the proposed study will have broad implications regarding the physiological role of
      TNF-alpha on the inflammatory cascade, cardiovascular indices and endothelial function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-reactive Protein (CRP)</measure>
    <time_frame>6 months</time_frame>
    <description>As a measure of C-reactive protein (CRP), which is an inflammatory marker, Log10 of the CRP at 6 months is reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-6 (IL-6)</measure>
    <time_frame>6 months</time_frame>
    <description>6 month value of IL-6 (pg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>6 months</time_frame>
    <description>The ratio of circulating high molecular weight (HMW) adiponectin to total adiponectin ratio (HMW:total Adiponectin) at 6 months is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose Tolerance</measure>
    <time_frame>6 months</time_frame>
    <description>Fasting glucose (mg/dL) at 6mo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>6 months</time_frame>
    <description>Reactive Hyperemia Index (RHI) using peripheral artery tonometry (using Endo-PAT 2000). Peripheral artery tonometry measures blood flow in the tip of the index finger at baseline and in response to vaso-occlusion (inflated blood pressure cuff). The reactive hyperemia index is an index of vasodilation after occlusion compared to baseline. A higher value indicates better vasoreactivity. As this is a relatively new test, there are no thoroughly validated clinically utilized norms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Blood Cell (WBC) Count</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in WBC during study (WBC at six months minus WBC at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Echo Ejection Fraction (EF)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>change in EF (6mo - baseline). Please note that the value given is the absolute change in EF (which has units of percent), not the percent change in the variable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition</measure>
    <time_frame>6 months</time_frame>
    <description>6 month visceral adipose tissue (cm^2) - cross-sectional area of the visceral adipose tissue at the level of the 4th lumbar vertebrae was measured using single-slice abdominal computed tomography (CT) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Necrosis Factor (TNF) Receptor</measure>
    <time_frame>6 months</time_frame>
    <description>Circulating concentrations of Tumor necrosis factor receptor 2 (TNFR2) at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Adipocytokines</measure>
    <time_frame>6 months</time_frame>
    <description>circulating resistin at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Levels</measure>
    <time_frame>6 months</time_frame>
    <description>total cholesterol (mg/dL) at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipocyte Messenger Ribonucleic Acid (mRNA) Levels of Adipocytokines Including Tumor Necrosis Factor (TNF) -Alpha</measure>
    <time_frame>6 months</time_frame>
    <description>fold-change in subcutaneous adipose tissue expression of TNF-alpha (mRNA) after 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months</description>
    <arm_group_label>Etanercept</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hyperinsulinemia in the upper quartile of the non-diabetic population defined as &gt;= 10
             mU/mL (based on Framingham Data, oral communication, James Meigs, MD) or fasting
             glucose 110-126 mg/dL

          2. Plus two of the following:

               -  Abdominal obesity defined by waist hip ratio &gt; 0.90 for men and &gt; 0.85 for women
                  and BMI &gt; 30 kg/m2

               -  Dyslipidemia including serum triglycerides &gt;= 150 mg/dl or serum high density
                  lipoprotein (HDL) &lt; 0.9 mmol/L for men (35 mg/dL) and &lt; 1.0 mmol/L (39mg/dL) for
                  women

               -  Hypertension defined as blood pressure &gt;= 140/90 or on medication

        Exclusion Criteria:

          1. Age &lt; 18 or &gt; 60 years

          2. Body mass index (BMI) &lt; 30 kg/m2

          3. Positive tuberculosis (purified protein derivative [PPD]) skin test (5mm induration or
             more) on screening

          4. Mycobacterial disease treated less than 6 months.

          5. Current or recurrent infection or any underlying condition that may predispose to
             infection or anyone who has been admitted to the hospital due to bacteremia, pneumonia
             or any other serious infection.

          6. Therapy with glucocorticoid or immunosuppressant at time of recruitment or within past
             3 months.

          7. Prior or concurrent cyclophosphamide therapy

          8. Use of a live vaccine 90 days prior to, or during this study.

          9. History of blood dyscrasia including any kind of anemia, thrombocytopenia,
             pancytopenia. Women with a reversible cause of anemia that has resolved will be
             eligible.

         10. Hemoglobin &lt; 11 g/dl

         11. History of malignancy (except patients with surgically cured basal cell or squamous
             cell skin cancers who will be eligible)

         12. History of organ transplantation

         13. HIV-positive status determined by HIV test at screening or known history of any other
             immuno-suppressing disease.

         14. Hepatitis B or hepatitis C infection detected at screening, lupus (SLE), history of
             multiple sclerosis, transverse myelitis, optic neuritis or epilepsy

         15. Patients with known autoimmune or inflammatory conditions (excluding patients with
             stable, treated hypothyroidism)

         16. Severe comorbidities (diabetes mellitus requiring insulin, congestive heart failure
             (CHF) (EF&lt;50% at baseline will be exclusionary) of any severity, myocardial infarction
             (MI), cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 3
             months of screening visit, unstable angina pectoris, oxygen-dependent severe pulmonary
             disease

         17. Uncontrolled systolic blood pressure &gt; 150 mmHg or diastolic blood pressure &gt; 100 mmHg

         18. Fasting blood glucose &gt; 126 mg/dL

         19. Creatinine &gt; 1.5

         20. Current use of insulin, any oral anti-hyperglycemic agents (including insulin
             sensitizing agents). Initiation of insulin, oral hypoglycemics, or insulin sensitizing
             agents during the study will result in discontinuation from the study.

         21. Initiation of statins, niacin, antihypertensive or fibrate therapy within 6 weeks of
             the study. Chronic use of fibrates, niacin, or antihypertensives for &gt; 6 weeks prior
             to study initiation at a stable dose is not exclusionary, but chronic use of statins
             for &gt; 6 months is exclusionary. Initiation of statins, fibrates, niacin or
             antihypertensive treatments during the study is not exclusionary but will be
             considered in the analysis (see Protection against risks).

         22. Positive pregnancy test or lactating females

         23. Women of child-bearing potential not currently using non-hormonal birth control
             methods including barrier methods (intrauterine device [IUD], condoms, diaphragms) or
             abstinence

         24. Subject is currently enrolled in another investigational device or drug trial(s), or
             subject has received other investigational agent(s) within 28 days of baseline visit.

         25. Subjects who have known hypersensitivity to Enbrel or any of its components or who is
             known to have antibodies to etanercept

         26. Concurrent sulfasalazine therapy

         27. History of recent alcohol or substance abuse (&lt; 1 year)

         28. Any condition judged by the patient's physician to cause this clinical trial to be
             detrimental to the patient.

         29. History of non-compliance with other therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven K Grinspoon</last_name>
    <role>Principal Investigator</role>
    <affiliation>MGH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2006</study_first_submitted>
  <study_first_submitted_qc>December 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2006</study_first_posted>
  <results_first_submitted>August 31, 2010</results_first_submitted>
  <results_first_submitted_qc>November 3, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2010</results_first_posted>
  <last_update_submitted>November 3, 2010</last_update_submitted>
  <last_update_submitted_qc>November 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Steven Grinspoon, MD</name_title>
    <organization>Massachusetts General Hospital</organization>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Visceral adiposity</keyword>
  <keyword>TNF</keyword>
  <keyword>Adiponectin</keyword>
  <keyword>glucose tolerance</keyword>
  <keyword>endothelial function</keyword>
  <keyword>metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period 12/2006 to 3/2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
        </group>
        <group group_id="P2">
          <title>Etanercept</title>
          <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 Month Visit</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
        </group>
        <group group_id="B2">
          <title>Etanercept</title>
          <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="8"/>
                    <measurement group_id="B2" value="41" spread="9"/>
                    <measurement group_id="B3" value="45" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>C-reactive Protein (CRP)</title>
        <description>As a measure of C-reactive protein (CRP), which is an inflammatory marker, Log10 of the CRP at 6 months is reported</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Etanercept</title>
            <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein (CRP)</title>
          <description>As a measure of C-reactive protein (CRP), which is an inflammatory marker, Log10 of the CRP at 6 months is reported</description>
          <units>Log10 mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.06"/>
                    <measurement group_id="O2" value="0.68" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>treatment effect (etanercept vs. placebo) using ANCOVA including baseline CRP, age, and race</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-6 (IL-6)</title>
        <description>6 month value of IL-6 (pg/mL)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Etanercept</title>
            <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-6 (IL-6)</title>
          <description>6 month value of IL-6 (pg/mL)</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="1.1"/>
                    <measurement group_id="O2" value="11.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>within subject percent changes calculated for each timepoint and repeated measures ANCOVA controlling for age and race performed</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Repeated Measures ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adiponectin</title>
        <description>The ratio of circulating high molecular weight (HMW) adiponectin to total adiponectin ratio (HMW:total Adiponectin) at 6 months is reported.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Etanercept</title>
            <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Adiponectin</title>
          <description>The ratio of circulating high molecular weight (HMW) adiponectin to total adiponectin ratio (HMW:total Adiponectin) at 6 months is reported.</description>
          <units>(ratio)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.08"/>
                    <measurement group_id="O2" value="0.40" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>within subject percent changes were calculated for each time point, then repeated measures ANCOVA controlling for age and race performed</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Repeated Measures ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Tolerance</title>
        <description>Fasting glucose (mg/dL) at 6mo</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Etanercept</title>
            <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Tolerance</title>
          <description>Fasting glucose (mg/dL) at 6mo</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" spread="5"/>
                    <measurement group_id="O2" value="91" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>percent change calculated then repeated measures ANCOVA performed controlling for age and race</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>repeated measures ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelial Function</title>
        <description>Reactive Hyperemia Index (RHI) using peripheral artery tonometry (using Endo-PAT 2000). Peripheral artery tonometry measures blood flow in the tip of the index finger at baseline and in response to vaso-occlusion (inflated blood pressure cuff). The reactive hyperemia index is an index of vasodilation after occlusion compared to baseline. A higher value indicates better vasoreactivity. As this is a relatively new test, there are no thoroughly validated clinically utilized norms.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Etanercept</title>
            <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Function</title>
          <description>Reactive Hyperemia Index (RHI) using peripheral artery tonometry (using Endo-PAT 2000). Peripheral artery tonometry measures blood flow in the tip of the index finger at baseline and in response to vaso-occlusion (inflated blood pressure cuff). The reactive hyperemia index is an index of vasodilation after occlusion compared to baseline. A higher value indicates better vasoreactivity. As this is a relatively new test, there are no thoroughly validated clinically utilized norms.</description>
          <units>(index)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.11"/>
                    <measurement group_id="O2" value="2.0" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA controlling for baseline value, age, race</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>White Blood Cell (WBC) Count</title>
        <description>Change in WBC during study (WBC at six months minus WBC at baseline)</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Etanercept</title>
            <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>White Blood Cell (WBC) Count</title>
          <description>Change in WBC during study (WBC at six months minus WBC at baseline)</description>
          <units>th/cumm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.23"/>
                    <measurement group_id="O2" value="-0.04" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Echo Ejection Fraction (EF)</title>
        <description>change in EF (6mo - baseline). Please note that the value given is the absolute change in EF (which has units of percent), not the percent change in the variable.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Etanercept</title>
            <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Echo Ejection Fraction (EF)</title>
          <description>change in EF (6mo - baseline). Please note that the value given is the absolute change in EF (which has units of percent), not the percent change in the variable.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.7"/>
                    <measurement group_id="O2" value="-1.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition</title>
        <description>6 month visceral adipose tissue (cm^2) - cross-sectional area of the visceral adipose tissue at the level of the 4th lumbar vertebrae was measured using single-slice abdominal computed tomography (CT) scan</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Etanercept</title>
            <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition</title>
          <description>6 month visceral adipose tissue (cm^2) - cross-sectional area of the visceral adipose tissue at the level of the 4th lumbar vertebrae was measured using single-slice abdominal computed tomography (CT) scan</description>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206" spread="18"/>
                    <measurement group_id="O2" value="186" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA controlling for baseline value, age, race</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Necrosis Factor (TNF) Receptor</title>
        <description>Circulating concentrations of Tumor necrosis factor receptor 2 (TNFR2) at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Etanercept</title>
            <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Necrosis Factor (TNF) Receptor</title>
          <description>Circulating concentrations of Tumor necrosis factor receptor 2 (TNFR2) at 6 months</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2573" spread="148"/>
                    <measurement group_id="O2" value="4518" spread="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>within subject percent changes calculated then repeated measures ANCOVA controlling for age and race performed</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Adipocytokines</title>
        <description>circulating resistin at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Etanercept</title>
            <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Other Adipocytokines</title>
          <description>circulating resistin at 6 months</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="0.5"/>
                    <measurement group_id="O2" value="8.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>within subject percent changes calculated then repeated measures ANCOVA performed controlling for age and race</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Repeated Measures ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Levels</title>
        <description>total cholesterol (mg/dL) at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Etanercept</title>
            <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Levels</title>
          <description>total cholesterol (mg/dL) at 6 months</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" spread="9"/>
                    <measurement group_id="O2" value="201" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA controlling for baseline value, age, and race</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adipocyte Messenger Ribonucleic Acid (mRNA) Levels of Adipocytokines Including Tumor Necrosis Factor (TNF) -Alpha</title>
        <description>fold-change in subcutaneous adipose tissue expression of TNF-alpha (mRNA) after 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Etanercept</title>
            <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Adipocyte Messenger Ribonucleic Acid (mRNA) Levels of Adipocytokines Including Tumor Necrosis Factor (TNF) -Alpha</title>
          <description>fold-change in subcutaneous adipose tissue expression of TNF-alpha (mRNA) after 6 months</description>
          <units>fold-change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.7"/>
                    <measurement group_id="O2" value="1.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo injections, subcutaneously, twice weekly x 3 months, then once weekly x 3 months</description>
        </group>
        <group group_id="E2">
          <title>Etanercept</title>
          <description>Etanercept 50mg subcutaneously twice weekly x 3 months, then once weekly x 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SNOMED CT</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Operative Surgical Procedure</sub_title>
                <description>1 placebo subject had surgery for cervical disc repair, and 1 etanercept subject had planned (elective) knee surgery</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <description>1 subject receiving etanercept developed transient parasthesia in leg after giving study medication. Study drug was discontinued and symptoms resolved.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <description>Exacerbation of pre-existing schizophrenia requiring hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Foot Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dental Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bakers Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <description>Mild intermittent symptoms of tingling in hands and feet in a subject who had also experienced these symptoms prior to study participation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven K. Grinspoon</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-9109</phone>
      <email>sgrinspoon@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

